JP6552636B2 - 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン - Google Patents

血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン Download PDF

Info

Publication number
JP6552636B2
JP6552636B2 JP2017551176A JP2017551176A JP6552636B2 JP 6552636 B2 JP6552636 B2 JP 6552636B2 JP 2017551176 A JP2017551176 A JP 2017551176A JP 2017551176 A JP2017551176 A JP 2017551176A JP 6552636 B2 JP6552636 B2 JP 6552636B2
Authority
JP
Japan
Prior art keywords
amino acid
seq
ankyrin repeat
acid sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017551176A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018511327A5 (enExample
JP2018511327A (ja
Inventor
タリッサ バッカー
タリッサ バッカー
ミヒャエル テー シュトゥンプ
ミヒャエル テー シュトゥンプ
ハンス カスパル ビンツ
ハンス カスパル ビンツ
ダグラス フィリップス
ダグラス フィリップス
イグナシオ ドラド
イグナシオ ドラド
フォーラー　パトリック
パトリック フォーラー
フリーデル ヴェー メルツ
フリーデル ヴェー メルツ
イーヴォ ゾンダーエッガー
イーヴォ ゾンダーエッガー
ダニエル シュタイナー
ダニエル シュタイナー
ゲオルギエヴァ マヤ ガロッティ
ゲオルギエヴァ マヤ ガロッティ
サリバ ヨハン アブラム
サリバ ヨハン アブラム
Original Assignee
モレキュラー パートナーズ アクチェンゲゼルシャフト
モレキュラー パートナーズ アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー パートナーズ アクチェンゲゼルシャフト, モレキュラー パートナーズ アクチェンゲゼルシャフト filed Critical モレキュラー パートナーズ アクチェンゲゼルシャフト
Publication of JP2018511327A publication Critical patent/JP2018511327A/ja
Publication of JP2018511327A5 publication Critical patent/JP2018511327A5/ja
Application granted granted Critical
Publication of JP6552636B2 publication Critical patent/JP6552636B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2017551176A 2015-04-02 2016-04-01 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン Active JP6552636B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15162502.7 2015-04-02
EP15162511 2015-04-02
EP15162511.8 2015-04-02
EP15162502 2015-04-02
PCT/EP2016/057272 WO2016156596A1 (en) 2015-04-02 2016-04-01 Designed ankyrin repeat domains with binding specificity for serum albumin

Publications (3)

Publication Number Publication Date
JP2018511327A JP2018511327A (ja) 2018-04-26
JP2018511327A5 JP2018511327A5 (enExample) 2018-11-22
JP6552636B2 true JP6552636B2 (ja) 2019-07-31

Family

ID=55650423

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017551176A Active JP6552636B2 (ja) 2015-04-02 2016-04-01 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン

Country Status (20)

Country Link
US (3) US9458211B1 (enExample)
EP (2) EP3277711B9 (enExample)
JP (1) JP6552636B2 (enExample)
KR (2) KR20220109488A (enExample)
CN (1) CN107454904A (enExample)
AU (3) AU2016240220B2 (enExample)
BR (1) BR112017020986A2 (enExample)
CA (1) CA2979602C (enExample)
CL (1) CL2017002454A1 (enExample)
CO (1) CO2017009954A2 (enExample)
ES (1) ES2953482T3 (enExample)
IL (2) IL276944B (enExample)
MX (2) MX2022008302A (enExample)
MY (1) MY179505A (enExample)
NZ (1) NZ735803A (enExample)
PH (1) PH12017501792B1 (enExample)
RU (1) RU2769470C2 (enExample)
SA (1) SA517390092B1 (enExample)
SG (1) SG11201707606RA (enExample)
WO (1) WO2016156596A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
CN113278077A (zh) * 2010-11-26 2021-08-20 分子组合公司 设计的与血清白蛋白结合的重复蛋白
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US10253094B2 (en) 2016-07-20 2019-04-09 Aerpio Therapeutics, Inc. Antibodies that target human protein tyrosine phosphatase-beta (HPTP-beta) and methods of use thereof to treat ocular conditions
ES2953516T3 (es) 2016-09-22 2023-11-14 Molecular Partners Ag Proteínas de unión recombinantes y su uso
WO2019011167A1 (zh) * 2017-07-12 2019-01-17 四川科伦博泰生物医药股份有限公司 双特异性重组蛋白
CN111225976A (zh) * 2017-08-18 2020-06-02 剑桥企业有限公司 模块化结合蛋白
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
JP2022521353A (ja) * 2019-03-22 2022-04-06 リフレクション ファーマシューティカルズ， インコーポレイテッド Ｖｅｇｆのためのｄ－ペプチド性化合物
CN114222757A (zh) 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
EP3980443A1 (en) 2019-06-04 2022-04-13 Molecular Partners AG Multispecific proteins
JP7611173B2 (ja) * 2019-06-04 2025-01-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｆａｐ結合タンパク質及びそれらの使用
CA3138805A1 (en) * 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
BR112022011177A2 (pt) * 2019-12-11 2022-09-27 Molecular Partners Ag Domínios de repetição de anquirina projetados com resíduos de superfície alterados
WO2021116470A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
WO2021224686A1 (en) * 2020-05-06 2021-11-11 Molecular Partners Ag Novel ankyrin repeat binding proteins and their uses
WO2021229076A1 (en) 2020-05-14 2021-11-18 Molecular Partners Ag Recombinant cd40 binding proteins and their use
EP4149959A1 (en) * 2020-05-14 2023-03-22 Molecular Partners AG Multispecific proteins
EP3957649A1 (en) 2020-08-18 2022-02-23 Athebio AG Improved n-terminal capping modules of ankyrin repeat domains
AU2021403658A1 (en) 2020-12-16 2023-06-29 Molecular Partners Ag Recombinant cd3 binding proteins and their use
CA3202358A1 (en) * 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
US20240150475A1 (en) * 2021-03-09 2024-05-09 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024508969A (ja) 2021-03-09 2024-02-28 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規のＤＡＲＰｉｎに基づくＣＤ３３エンゲージャ
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
IL305677A (en) * 2021-03-09 2023-11-01 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
US20250074994A1 (en) * 2021-04-09 2025-03-06 Molecular Partners Ag Novel darpin based cd70 engagers
EP4447990A1 (en) 2021-12-14 2024-10-23 Molecular Partners AG Designed repeat domains with dual binding specificity and their use
CN114957426B (zh) * 2022-06-02 2023-05-16 华南师范大学 Sp6rars及其在防治蜚蠊目昆虫中的应用
WO2024028278A1 (en) 2022-08-01 2024-02-08 Molecular Partners Ag Charge modified designed repeat domains and their use
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
AR131869A1 (es) 2023-02-17 2025-05-07 Ablynx Nv POLIPÉPTIDOS QUE SE UNEN AL RECEPTOR DE Fc NEONATAL
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
EP4724486A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd2 binding proteins and their use
EP4724473A1 (en) 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd47 binding proteins and their use
WO2025073871A1 (en) 2023-10-03 2025-04-10 Bicycletx Limited Bicyclic peptide ligand complexes specific for tfr1
WO2025146490A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Recombinant cd117 binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent
WO2025146487A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Multispecific binding proteins
WO2025163144A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Recombinant mesothelin binding proteins and their use
WO2025163082A1 (en) 2024-01-31 2025-08-07 Molecular Partners Ag Dll3-specific binding constructs and their use in radiotherapy
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager
WO2026013280A1 (en) 2024-07-11 2026-01-15 Johann Wolfgang Goethe-Universität Frankfurt am Main Designed ankyrin repeat proteins binding p53, and uses thereof
WO2026093563A2 (en) 2024-10-31 2026-05-07 Molecular Partners Ag Multispecific binding proteins and their use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
JP5291279B2 (ja) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ 反復モジュールを含む反復タンパク質の集合体
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
EP2292246A1 (en) 2004-11-12 2011-03-09 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus
AU2006249144B2 (en) 2005-05-18 2011-11-17 Ablynx Nv Improved NanobodiesTM against Tumor Necrosis Factor-alpha
MX2008000345A (es) 2005-07-08 2008-04-02 Univ Zuerich Visualizacion en fagos usando transcolocacion contraduccional de polipeptidos de fusion.
DK2402754T4 (da) 2006-03-06 2023-08-28 Amunix Operating Inc Ustrukturerede rekombinante polymerer og anvendelser deraf
JP5351889B2 (ja) 2007-06-21 2013-11-27 テクニシェ ユニバーシタット ミュンヘン インビボおよび／またはインビトロ安定性が増大した生物学的に活性なタンパク質
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
MX359570B (es) 2008-11-03 2018-10-01 Molecular Partners Ag Proteinas de union que inhiben la interaccion en el receptor de vegf-a.
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
NZ604805A (en) * 2010-07-09 2014-09-26 Affibody Ab Polypeptides
EP2596359A1 (en) * 2010-07-19 2013-05-29 F.Hoffmann-La Roche Ag Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
SG190362A1 (en) * 2010-11-24 2013-06-28 Glaxo Group Ltd Multispecific antigen binding proteins targeting hgf
CN113278077A (zh) 2010-11-26 2021-08-20 分子组合公司 设计的与血清白蛋白结合的重复蛋白
WO2012149439A2 (en) 2011-04-29 2012-11-01 Janssen Biotech, Inc. Il4/il13 binding repeat proteins and uses
EP2867360B1 (en) 2012-06-28 2019-05-08 Molecular Partners AG Designed ankyrin repeat proteins binding to platelet-derived growth factor
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白

Also Published As

Publication number Publication date
KR102427117B1 (ko) 2022-07-29
CL2017002454A1 (es) 2018-05-25
US9458211B1 (en) 2016-10-04
EP4272838A3 (en) 2024-01-10
MX2017012485A (es) 2018-04-11
EP4272838A2 (en) 2023-11-08
SG11201707606RA (en) 2017-10-30
IL276944A (en) 2020-10-29
IL254788A0 (en) 2017-12-31
MX393655B (es) 2025-03-24
ES2953482T3 (es) 2023-11-13
EP3277711A1 (en) 2018-02-07
US20190263869A1 (en) 2019-08-29
CA2979602C (en) 2022-12-20
AU2021286418A1 (en) 2022-01-20
CA2979602A1 (en) 2016-10-06
RU2769470C2 (ru) 2022-04-01
CN107454904A (zh) 2017-12-08
AU2016240220A1 (en) 2017-10-19
RU2017134456A3 (enExample) 2019-10-08
US20160362453A1 (en) 2016-12-15
BR112017020986A2 (pt) 2018-08-14
AU2016240220B2 (en) 2019-11-21
JP2018511327A (ja) 2018-04-26
IL254788B (en) 2020-09-30
US10155791B2 (en) 2018-12-18
WO2016156596A1 (en) 2016-10-06
EP3277711B9 (en) 2023-08-16
US11332501B2 (en) 2022-05-17
NZ735803A (en) 2021-12-24
MX2022008302A (es) 2023-02-28
KR20170131515A (ko) 2017-11-29
IL276944B (en) 2022-07-01
PH12017501792A1 (en) 2019-01-21
RU2017134456A (ru) 2019-04-03
CO2017009954A2 (es) 2018-02-20
EP3277711B1 (en) 2023-06-07
MY179505A (en) 2020-11-09
EP3277711C0 (en) 2023-06-07
SA517390092B1 (ar) 2022-03-03
KR20220109488A (ko) 2022-08-04
AU2020201264A1 (en) 2020-03-12
US20160289285A1 (en) 2016-10-06
HK1244009A1 (en) 2018-07-27
AU2021286418B2 (en) 2024-01-04
PH12017501792B1 (en) 2022-07-20

Similar Documents

Publication Publication Date Title
AU2021286418B2 (en) Designed ankyrin repeat domains with binding specificity for serum albumin
US20210130420A1 (en) Recombinant binding proteins targeting her2 and serum albumin, and their uses
EP3004152B1 (en) Designed ankyrin repeat proteins binding to hepatocyte growth factor
HK1244009B (en) Designed ankyrin repeat domains with binding specificity for serum albumin
RU2778346C2 (ru) Рекомбинантные связывающие белки и их применение
HK40006908A (en) Recombinant binding proteins and their use
HK40006908B (en) Recombinant binding proteins and their use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180312

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181003

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20181003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181010

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20181011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190328

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190424

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190604

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190702

R150 Certificate of patent or registration of utility model

Ref document number: 6552636

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250